Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)

Complication of Renal Dialysis Clinical Trial

— ARChIVED  

Official title:

Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02764736
• Other study ID #: 4802
• Status: Withdrawn
• Phase: N/A
• First received: March 18, 2016
• Last updated: May 16, 2017
• Start date: March 4, 2016
• Est. completion date: March 22, 2017

Study information

• Verified date: May 2017
• Source: Albert Einstein Healthcare Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average Epogen utilization. Statin naive patients on maintenance HD will be started on 20mg atorvastatin daily for weeks and then titrated up to 40mg atorvastatin daily for an additional 12 weeks. Patient's inflammatory markers (ferritin, CRP) and weekly Epogen usage will be monitored.

Description:

Patients will be identified and consented. After informed consent is obtained, baseline demographic information, past medical history, dialysis specific information, and laboratory metrics (lipid profile, inflammatory markers) will be obtained from the electronic medical records. For the first 12 weeks, all subjects will be instructed to take one 20mg atorvastatin tablet daily; atorvastatin tablets will be dispensed by the research team in 30-tablet increments every month to ensure compliance and prevent diversion. Subjects will undergo standard-of-care hemodialysis with routine hemoglobin monitoring and Epogen titration according to the dialysis center protocol. Every two weeks, they will be assessed by a research coordinator who will monitor for medication adverse effects (see attached patient survey) and medication compliance (pill counts) at alternating visits. After 12 weeks, lipid profile and inflammatory markers will be rechecked or obtained from the electronic medical record. For the subsequent 12 weeks (ie. weeks 12-24), subjects will be instructed to take two 20mg atorvastatin tablets (40mg total) daily. If the subject is unable to tolerate 40mg of atorvastatin daily due to medication adverse effects, they will continue to take 20mg atorvastatin daily for the remainder of the trial. Epogen will be titrated and subjects will be monitored as above. At the completion of the study, a lipid panel and inflammatory markers will be checked for a third time. Epogen usage and dialysis specific information will be recorded continuously throughout the study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 22, 2017
• Est. primary completion date: March 22, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 110 Years

Eligibility

Inclusion Criteria:

• Stable on Hemoglobin levels on Epogen therapy (Hgb between 9.5-11.5 for prior 3 weeks)

• No statin usage during the prior 3 months

• Complaint with hemodialysis and medications

Exclusion Criteria:

• Prior history of myocardial infarction, stroke or vascular disease

• Prior hospitalization within the past 15 days

• Prior episodes of significant bleeding (trauma, GI bleed, GU bleed, menorrhagia) in the prior 15 days

• Liver disease

• Active malignancy

• Hematologic disorder

Related Conditions & MeSH terms

• Complication of Renal Dialysis
• Inflammation

Intervention

Drug:
• Atorvastatin
Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Albert Einstein Healthcare Network

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Epoetin alfa (Epogen) utilization measured in units per week	The amount of epoetin alfa, measured in units, needed to maintain a patient's hemoglobin between 11.0 and 12.0 gm/dL	24 weeks
Secondary	C-reactive protein, ferritin levels		24 weeks
Secondary	Total cholesterol level, LDL level, HDL level		24 weeks